ALKERMES | ALKS - Capitale Di Prestito





Capitale Di Prestito Cambiamento Data
AbbVie USD 64.53B 5.59B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 1.48B 7.23M 2026-06
Amgen USD 51.86B 27M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
J&J USD 37.34B 183M 2026-06
Malin Corporation EUR 0 0 2024-12
Merck USD 51.08B 4.41B 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Otsuka Holdings JPY 164.66B 301M 2026-06
Ovoca Bio EUR 0 0 2021-06
Pfizer USD 60.5B 70M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12